ErSO/TEQ103forBreastCancer

Formerly #ErSO, then #SERA2. Now #TEQ103! Clinical trial is set for 2025. #TEQ103 targets Er+ #MBC, eliminating it. Developed by #Oncoteq and #Cureteq.

[ErSO/TEQ103forBreastCancer @ErSOActivism]

#ErSO➡️#Sera2
➡️#TEQ103

[Dirk the Cancer Fighter @rushmorealum]

@PresCancerPanel

[ErSO/TEQ103forBreastCancer @ErSOActivism]

not exactly #TEQ103 but the new drug set for trial in May does create massive er stress in breast cancer cells! let’s go #ERX-315!

[Dirk the Cancer Fighter @rushmorealum]

Update !!

#ERX315 for #mbc is looking to go to trial in Australia in May.

ERX-315 targets BC mutations “inducing significant endoplasmic reticulum stress.” Ie blows #MBC up!

ERX-315 does not induce cell death in normal cells and is non-toxic in animal models.

Here is an email from the company @etirarx :

[lori caref @lor8ena]

@ErSOActivism how can it be 5-7 years for a TEQ103 trial? please help expedite!

[ErSO/TEQ103forBreastCancer @ErSOActivism]

@ListenToBeBlunt @PartexNV right to try, fast track, anything to move #mbc patients and #TEQ103 treatment closer. let’s hope #AI helps speed up the process too Blunt.

[ErSO/TEQ103forBreastCancer @ErSOActivism]

@PartexNV is there anyway to expedite #Teq103? phase 0 like @RNAoncology pulled off with TTX-MC138? Or utilizing AI? As current #mbc patients we really can’t wait years. There must be a clever way

[ErSO/TEQ103forBreastCancer @ErSOActivism]

reminder

[Partex NV @PartexNV]

@PartexNV NV will be in San Francisco from Jan 7th- 11th 2024!

Our CEO, Dr. Gunjan Bhardwaj & CCO, Dr. Frank Grams will be attending various events around the #JPM Healthcare Conference 2024.

See you there! Arrange meetup: [email protected]

#JPMorgan #JPM2024 #events #healthcare

[Dirk the Cancer Fighter @rushmorealum]

#SABCS23 = bit meh
got a couple of things this year for #mbc with certain indications…

truqap (capivasertib) er+
her2- (pik3ca, akt1,pten)
priority review

orserdu (elacestrant) er+ her2- (w/ esr1mut) fast track

#ErSO aka #TEQ103 finally found a home. Good. But jeesh, the timeline needs to hurry up. How about a phase 0 @PartexNV ?? Anything to speed things along for existing #mbc patients. We can’t wait 5 years for tech thats been sitting around

Let’s keep an eye on @etirarx and #ERX315 in Q1.

One thing is for sure, need more in #24.

[Dirk the Cancer Fighter @rushmorealum]

AVA6000 is being trialed for a bunch of cancers including #mbc.
in phase 1.

AVA6000 is a modified version of doxorubicin - and blasts cancer cells without the terrible tox.
Doxy is known as the “red devil” or “red death” because of its color and rough side effects.
a very potent but less toxic version could be a game changer

[ErSO/TEQ103forBreastCancer @ErSOActivism]

anyone know? or is the jury still out?

[Dirk the Cancer Fighter @rushmorealum]

@stolaney1 such a general question but are these newer ADCs differentiated enough from Enhertu and Trodelvy that they may work if those lines have been exhausted?

[Partex NV @PartexNV]

Our Cureteq AG team has closed its successful in-licensing deal for the first-in-class compound TEQ103.

Read more about it here: https://t.co/WNYUFaCcdk

#pharmanews #health #drugassets #healthcare #patients #oncology #CancerResearch

[Dirk the Cancer Fighter @rushmorealum]

An IND for #TEQ103 (the drug formerly known as #ErSO) could speed up the development process as other expedited programs such as breakthrough therapy designation might follow

[Cancer Center at Illinois @CancerCenterIL]

A compound developed by Cancer Center at Illinois researchers is one step closer to clinical trials for #breastcancer patients.

👉 Learn more about what's next: https://t.co/f1rqj5yvvk

[Dirk the Cancer Fighter @rushmorealum]

The #ErSO has landed!

#ErSO is now #TEQ103.

#Oncoteq and its parent company #Cureteq are now developing #TEQ103 with the goal of a trial in 2025.

Oncoteq is a cool Swiss company that uses AI to accelerate development. I’m sounding greedy but hopefully things move along faster than first thought or there’s compassionate use when needed.
In any case, good news today!

see attached press release:

[ErSO/TEQ103forBreastCancer @ErSOActivism]

@rushmorealum @ksaraholland @SystemsOncology isn’t very active on social media but are driving the narrative behind the scenes along with continued work by the creators of #ErSO-DFP at @CancerCenterIL @ChemistryUIUC .

[Dirk the Cancer Fighter @rushmorealum]

Hi @ksaraholland .

I came across #Cureteq while researching #Recursion and #Insilico.

your website quote stuck out:
“is using AI to help develop innovative medicines, with a particular focus on oncology.”

you’ve got one small molecule, M8891.
would you consider another one for #mbc, #ErSO-DFP?
There is “hidden value” with this molecule.

please just take a look.
The tech is amazing. Thanks.

[Dirk the Cancer Fighter @rushmorealum]

cf33 virus can deliver functional proteins to solid tumors.

theoretically, could cf33 deliver small molecule activator erso-dfp to solid #mbc tumors?

@SoCalYuman @SaulPriceman

[Dirk the Cancer Fighter @rushmorealum]

New drug approved for
Er+ Her2- #mbc .
But for tumors with specific gene alterations, such as PIK3CA, AKT1, or PTEN.

Drug is Truqap (capivasertib ) — used in combo with fulvestrant. It’s made by @AstraZeneca.

Truqap pfs is 7.3 months.
Another tool for the time being

[Dirk the Cancer Fighter @rushmorealum]

#mbc drug update :
#Lasofoxifene making strides for #mbc with esr1 mutation!

all started with @donaldmcdonnell and then KaitlynAndreano.
let’s keep it rolling @SermonixPharma

https://t.co/r5y13BkKap

[TransCode Therapeutics @RNAoncology]

Our CTO and Co-founder, Zdravka Medarova, will be presenting at TIDES Europe.